<?xml version="1.0" encoding="UTF-8"?>
<p>Although not yet commercially available, it is hoped that a vaccine for chikungunya is on the horizon. Two phase 1 clinical trials have shown a good safety and immunogenicity profile to date.
 <xref rid="rmv1978-bib-0142" ref-type="ref">142</xref>, 
 <xref rid="rmv1978-bib-0143" ref-type="ref">143</xref> A recent study that tested an insect‚Äêspecific alphavirus as the vaccine platform found promising results in mice and macaques, including immunogenicity after a single dose.
 <xref rid="rmv1978-bib-0144" ref-type="ref">144</xref>
</p>
